跳至主要内容
临床试验/NCT01257542
NCT01257542终止4 期

A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose, Pilot Study To Evaluate Efficacy Of Dextromethorphan Hydrobromide On Acute Cough In A Pediatric Population

Pfizer4 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
Pfizer
入组人数
140
试验地点
4
主要终点
Total Cough Count

研究概览

简要总结

15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.

详细描述

In light of protocol changes required due to methodological and operational issues, including background noise in cough recordings which could impact data interpretation, the study has been terminated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
6 Years 至 11 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male or female healthy children ages 6 to under 12 years who are symptomatic with a cough due to a cold or acute URTI characterized by:
  • Onset of cold/URTI symptoms occurring no more than 10 days prior to Visit 1;
  • At least 5 coughs during the second 30-minute period of the 60-minute baseline period.
  • General good health, aside from a common cold, and has no contraindications to the study or rescue medication

排除标准

  • Acute, subchronic, or chronic cough due to any other condition other than a common cold
  • History of clinically significant cardiovascular, pulmonary, hepatic, renal, neurological, hematological, autoimmune, psychiatric, metabolic, gastro-intestinal or endocrine disease

研究组 & 干预措施

Active

Experimental

干预措施: Dextromethorphan (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Total Cough Count

时间窗: Up to 6 hours post-dose

Total cough count was done by trained assessors using continuous digital video and audio recordings.

次要结局

  • Change From Baseline in Perceived Verbal Cough Severity Scale for 6 Hour Post-Dose Period(Baseline, 1, 2, 3, 4, 5, 6 hours post-dose)
  • Change From Baseline in Verbal Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6(Baseline, 1, 2, 3, 4, 5, 6 hours)
  • Change From Baseline in Perceived Numerical Cough Severity Scale for 6 Hour Post-Dose Period(Baseline, 1, 2, 3, 4, 5, 6 hour post-dose)
  • Change From Baseline in Numerical Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6(Baseline, 1, 2, 3, 4, 5, 6 hours)
  • Participants' Global Assessment of Cough: Cough Severity(Within 5 minutes after Hour 6)
  • Participants' Global Assessment of Cough: Relief From Cough(Within 5 minutes after Hour 6)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验